This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Cholestasis is a medical condition in which the flow of bile from the liver to the small intestine is blocked or reduced. Bile is an important fluid that helps to digest and absorb fats and certain vitamins. When it is blocked, it can cause a buildup of bile acids in the body, which can result in a variety of symptoms such as jaundice, dark urine, itching, nausea, and abdominal pain. Cholestasis can be caused by a variety of conditions, including liver disease, certain medications, and certain birth defects. The most common form of cholestasis is intrahepatic cholestasis, which is caused by a blockage in the bile ducts inside the liver. This blockage prevents the bile from reaching the small intestine. Extrahepatic cholestasis is caused by a blockage outside of the liver, such as in the gallbladder or bile ducts. Treatment for cholestasis depends on the underlying cause. For example, if it is caused by a medication, the doctor may recommend discontinuing the medication or switching to a different one. If it is caused by a liver disease, the doctor may recommend dietary changes or medications to help manage the condition. In some cases, surgery may be necessary to remove a blockage or to repair or replace a damaged liver. Cholestasis can be a serious condition, so it is important to seek medical attention as soon as possible if you think you may be experiencing cholestasis. With proper diagnosis and treatment, most people with cholestasis can recover and experience improved symptoms.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States